The ASCO 2025 meeting highlights crucial advancements in breast cancer treatments, emphasizing new clinical trials and the role of PIK3CA mutations. Positive results show improved progression-free survival with innovative treatment combinations.

The discussion includes emerging oral agents and the necessity of ESR1 mutation testing.

New PROTAC agents targeting estrogen receptors are introduced, showcasing the collaborative efforts of healthcare professionals in advancing cancer research.